Andressa Letícia Lopes da Silva, Thiago Pina Goes de Araújo, Shakira Cavalcante de Albuquerque Ferreira, Anderson Brandão Leite, João Kaycke Sarmento da Silva, Lilyana Waleska Nunes Albuquerque, Ana Rachel Vasconcelos de Lima, Herbert Charles Silva Barros, Leandro Rocha Silva, Edeildo Ferreira da Silva-Júnior, João Xavier de Araújo-Júnior, Vivaldo Moura Neto, Aline Cavalcanti de Queiroz, Magna Suzana Alexandre-Moreira
{"title":"作为多形性胶质母细胞瘤分子靶点的 PI3K 信号通路","authors":"Andressa Letícia Lopes da Silva, Thiago Pina Goes de Araújo, Shakira Cavalcante de Albuquerque Ferreira, Anderson Brandão Leite, João Kaycke Sarmento da Silva, Lilyana Waleska Nunes Albuquerque, Ana Rachel Vasconcelos de Lima, Herbert Charles Silva Barros, Leandro Rocha Silva, Edeildo Ferreira da Silva-Júnior, João Xavier de Araújo-Júnior, Vivaldo Moura Neto, Aline Cavalcanti de Queiroz, Magna Suzana Alexandre-Moreira","doi":"10.2174/1389203724666230830125102","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma multiforme (GBM) is the most common type of cancer that affects the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors worldwide, with 296,000 new cases reported per year. The first-choice treatment consists of surgical resection, radiotherapy, and adjuvant chemotherapy, which increases patients' survival by 15 months. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that effectively eliminate cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed via the PI3K pathway, against human glioblastoma.</p>","PeriodicalId":10859,"journal":{"name":"Current protein & peptide science","volume":" ","pages":"12-26"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme.\",\"authors\":\"Andressa Letícia Lopes da Silva, Thiago Pina Goes de Araújo, Shakira Cavalcante de Albuquerque Ferreira, Anderson Brandão Leite, João Kaycke Sarmento da Silva, Lilyana Waleska Nunes Albuquerque, Ana Rachel Vasconcelos de Lima, Herbert Charles Silva Barros, Leandro Rocha Silva, Edeildo Ferreira da Silva-Júnior, João Xavier de Araújo-Júnior, Vivaldo Moura Neto, Aline Cavalcanti de Queiroz, Magna Suzana Alexandre-Moreira\",\"doi\":\"10.2174/1389203724666230830125102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Glioblastoma multiforme (GBM) is the most common type of cancer that affects the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors worldwide, with 296,000 new cases reported per year. The first-choice treatment consists of surgical resection, radiotherapy, and adjuvant chemotherapy, which increases patients' survival by 15 months. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that effectively eliminate cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed via the PI3K pathway, against human glioblastoma.</p>\",\"PeriodicalId\":10859,\"journal\":{\"name\":\"Current protein & peptide science\",\"volume\":\" \",\"pages\":\"12-26\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current protein & peptide science\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.2174/1389203724666230830125102\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current protein & peptide science","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2174/1389203724666230830125102","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme.
Glioblastoma multiforme (GBM) is the most common type of cancer that affects the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors worldwide, with 296,000 new cases reported per year. The first-choice treatment consists of surgical resection, radiotherapy, and adjuvant chemotherapy, which increases patients' survival by 15 months. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that effectively eliminate cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed via the PI3K pathway, against human glioblastoma.
期刊介绍：
Current Protein & Peptide Science publishes full-length/mini review articles on specific aspects involving proteins, peptides, and interactions between the enzymes, the binding interactions of hormones and their receptors; the properties of transcription factors and other molecules that regulate gene expression; the reactions leading to the immune response; the process of signal transduction; the structure and function of proteins involved in the cytoskeleton and molecular motors; the properties of membrane channels and transporters; and the generation and storage of metabolic energy. In addition, reviews of experimental studies of protein folding and design are given special emphasis. Manuscripts submitted to Current Protein and Peptide Science should cover a field by discussing research from the leading laboratories in a field and should pose questions for future studies. Original papers, research articles and letter articles/short communications are not considered for publication in Current Protein & Peptide Science.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
